Immodulon Therapeutics Ltd.
Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Immodulon Therapeutics Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT03711188
- Locations
- 🇬🇧
St George's University Hospitals NHS Foundation Trust, London, United Kingdom
🇬🇧The Christie Hospital, Manchester, United Kingdom
Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer
- Conditions
- Metastatic Cancer
- Interventions
- First Posted Date
- 2017-01-04
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Immodulon Therapeutics Ltd
- Target Recruit Count
- 2
- Registration Number
- NCT03009058
- Locations
- 🇫🇷
Centre Léon Bérard, Dpt Medecine & INSERM, Lyon, France
🇫🇷Gustave Roussy Cancer Center, Villejuif, France
🇬🇧St George's University of London, Institute of Infection and Immunity, London, United Kingdom
A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001
- Conditions
- Malignant Melanoma
- First Posted Date
- 2012-03-21
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Immodulon Therapeutics Ltd
- Target Recruit Count
- 10
- Registration Number
- NCT01559818
- Locations
- 🇬🇧
St Georges University of London, London, United Kingdom
A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Radiation: SBRT
- First Posted Date
- 2012-02-28
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Immodulon Therapeutics Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT01539824
- Locations
- 🇬🇧
HCA International, The Sarah Cannon Research Institute, London, United Kingdom
🇬🇧The London Clinic, London, United Kingdom
A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients
- Conditions
- Melanoma
- First Posted Date
- 2011-03-04
- Last Posted Date
- 2012-12-06
- Lead Sponsor
- Immodulon Therapeutics Ltd
- Target Recruit Count
- 19
- Registration Number
- NCT01308762
- Locations
- 🇬🇧
HCA Clinical Trials Unit, 79 Harley Street,, London, United Kingdom
- Prev
- 1
- 2
- Next